Global pharmaceutical company Lupin Limited has announced the successful completion of its acquisition of VISUfarma B.V. from GHO Capital Partners LLP. This marks a key step in Lupin’s strategy to expand its specialty care portfolio and establish a stronger foothold in Europe.
With this acquisition, Lupin significantly strengthens its presence in the ophthalmology segment. VISUfarma brings a portfolio of over 60 branded products covering a wide range of eye care needs, including:
This expanded offering positions Lupin to address a broader spectrum of patient needs within the eye care market.
One of the biggest advantages of this acquisition is VISUfarma’s established commercial footprint across major European markets such as:
In addition to geographic reach, VISUfarma brings a highly experienced team with deep expertise in ophthalmology, strong relationships with healthcare professionals, and valuable local market insights. This gives Lupin an immediate operational and strategic advantage in the region.
The acquisition comes at a time when global demand for eye care solutions is rising steadily. Two key factors are driving this growth:
By integrating VISUfarma, Lupin is better positioned to deliver innovative solutions and meet this growing demand.
Vinita Gupta, CEO of Lupin, described the acquisition as a significant milestone for the company. She emphasized that VISUfarma adds a differentiated portfolio of innovative eye health products supported by an established commercial infrastructure. She also noted that the acquisition will not only be immediately accretive but will accelerate the expansion of Lupin’s specialty business in Europe.
Paolo Cioccetti, CEO Italy at VISUfarma, expressed enthusiasm about the partnership. He highlighted Lupin’s global expertise and commitment to ophthalmology, stating that the collaboration is expected to drive further growth and innovation in eye care across Europe and beyond.
This acquisition reinforces Lupin’s long-term focus on specialty pharmaceuticals and marks a strategic shift toward high-value therapeutic areas. By combining VISUfarma’s strong regional presence with its own global capabilities, Lupin is well-positioned to scale its ophthalmology business and strengthen its competitive position in the European market.
The completion of the VISUfarma acquisition represents more than just a portfolio expansion for Lupin. It is a strategic move aimed at building a strong, specialized presence in the global ophthalmology space. As demand for advanced eye care solutions continues to grow, this integration is expected to play a crucial role in shaping Lupin’s future growth trajectory.